Last updated: September 4, 2026
Omidenepag isopropyl is a prostanoid EP2 receptor agonist for lowering intraocular pressure in glaucoma and ocular hypertension. Its commercial products are Eybelis in Japan and Omlonti in the United States. The asset has a differentiated pharmacology and a large addressable glaucoma market, but its financial trajectory is constrained by established prostaglandin analogs, generic competition, limited public revenue disclosure, and dependence on market access and ophthalmology prescribing behavior.
The drug’s commercial value is concentrated in Japan and the United States. Japan provides the longest operating history, while the U.S. approval expanded the addressable market but placed the product against low-cost generic latanoprost, bimatoprost and travoprost.
What is omidenepag isopropyl and how does it work?
Omidenepag isopropyl is a prodrug converted to omidenepag, a selective EP2 receptor agonist. It increases aqueous humor outflow through the conventional trabecular pathway and the uveoscleral pathway, reducing intraocular pressure.
Unlike prostaglandin F2α analogs, omidenepag does not activate the FP receptor. This distinction is commercially relevant because FP agonists can cause conjunctival hyperemia, eyelash growth, iris pigmentation and deepening of the upper eyelid sulcus. Omidenepag was developed to provide pressure reduction without several class-associated cosmetic and ocular adverse effects.
| Attribute |
Omidenepag isopropyl |
| Drug class |
Selective EP2 receptor agonist |
| Active metabolite |
Omidenepag |
| Main indication |
Glaucoma and ocular hypertension |
| Primary dosage form |
Ophthalmic solution |
| Japan brand |
Eybelis |
| U.S. brand |
Omlonti |
| Developers |
Santen Pharmaceutical and UBE |
| U.S. commercial partner |
Bausch + Lomb |
| Administration |
Once daily in the approved U.S. regimen |
| Primary commercial alternatives |
Latanoprost, bimatoprost, travoprost, tafluprost, timolol, brimonidine and netarsudil |
When did omidenepag isopropyl receive regulatory approval?
Japan was the first major market. Santen received approval for Eybelis in 2018, and the product launched in Japan later that year. The Japanese indication covers glaucoma and ocular hypertension.
The U.S. Food and Drug Administration approved Omlonti in September 2022. The U.S. label covers reduction of elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. FDA approval was based on clinical studies showing pressure reduction compared with vehicle control. The approval expanded the product from a Japan-centered specialty ophthalmology asset into a product with access to the world’s largest branded pharmaceutical market.
Regulatory timeline
| Date |
Event |
| 2018 |
Japan approval and launch of Eybelis |
| 2021 |
Santen and Bausch + Lomb announced a U.S. commercialization agreement |
| September 2022 |
FDA approved Omlonti |
| 2022 onward |
U.S. commercial rollout through the Santen-Bausch + Lomb arrangement |
| Ongoing |
Expansion depends on formulary access, ophthalmologist adoption and differentiation from generic prostaglandins |
FDA approval does not establish broad reimbursement. Omlonti must compete for formulary placement against inexpensive generic products and established branded therapies.
What is the market size for omidenepag isopropyl?
The addressable market is the global glaucoma and ocular-hypertension market, not the smaller EP2 agonist segment. Glaucoma is a chronic disease requiring long-term treatment, which creates recurring prescription demand. The market includes primary open-angle glaucoma, ocular hypertension, normal-tension glaucoma in some treatment settings, and combination therapy for patients inadequately controlled on one agent.
The commercial opportunity is strongest in four areas:
- Patients who need additional pressure reduction after monotherapy.
- Patients who do not tolerate FP agonist-related cosmetic or ocular effects.
- Patients who require a non-FP mechanism.
- Patients for whom once-daily dosing improves adherence.
The largest barrier is treatment substitution. Generic latanoprost is widely available at a fraction of the price of Omlonti or Eybelis. Physicians and payers therefore require a clinical or tolerability rationale before using omidenepag in place of a generic first-line agent.
Competitive positioning
| Product |
Mechanism |
Commercial position |
| Latanoprost |
FP receptor agonist |
Low-cost generic first-line therapy |
| Bimatoprost |
Prostamide/FP-related activity |
Strong efficacy; generic competition |
| Travoprost |
FP receptor agonist |
Generic and branded availability |
| Tafluprost |
FP receptor agonist |
Preservative-free positioning in some markets |
| Netarsudil |
ROCK inhibitor |
Alternative mechanism; tolerability limits adoption |
| Omidenepag |
Selective EP2 receptor agonist |
Differentiated mechanism and non-FP profile |
| Timolol |
Beta blocker |
Low-cost option; systemic contraindications |
| Brimonidine |
Alpha-2 agonist |
Often used in combination or selected patients |
Omidenepag has greater differentiation against FP agonists than against other newer branded glaucoma products. Netarsudil competes for patients needing a nontraditional mechanism, while fixed combinations compete for convenience and adherence.
How has omidenepag isopropyl performed financially?
Public company filings do not provide a complete standalone revenue series for omidenepag isopropyl. Santen reports product and regional performance at an aggregated level, and Bausch + Lomb reports commercial results within broader product categories. As a result, product-specific revenue, gross margin and contribution profit cannot be established from public disclosures alone.
The financial trajectory can still be assessed by commercial stage:
| Period |
Financial interpretation |
| 2018-2021 |
Japan launch and market-building phase; revenue dependent on domestic uptake |
| 2022 |
U.S. approval created a new commercial opportunity but also added launch costs |
| 2023-2024 |
Early U.S. commercialization phase; sales dependent on formulary access and specialist adoption |
| Longer term |
Potential recurring growth if Omlonti gains share in intolerant, uncontrolled or combination-therapy patients |
The U.S. launch is strategically important because glaucoma treatment is chronic and prescriptions can persist for years. The revenue ramp is likely to be gradual rather than immediate. Ophthalmology products face payer restrictions, prior authorization, step edits and physician preference for generic prostaglandins.
Santen’s broader financial exposure is diversified across ophthalmic products, including products for dry eye, retinal disease and glaucoma. Omidenepag therefore is commercially important but is not the sole driver of company performance. Bausch + Lomb’s exposure is similarly diluted across contact lenses, surgical products, eye-care products and pharmaceutical products.
What drives omidenepag isopropyl market growth?
Clinical differentiation
The strongest demand driver is tolerability. Omidenepag’s EP2 mechanism avoids direct FP receptor activation, which may make it attractive for patients who develop iris pigmentation, eyelid changes or other prostaglandin-associated effects.
Clinical differentiation is more valuable in patients who have already failed or discontinued an FP agonist than in untreated patients facing a low-cost generic first-line option.
Combination therapy
Many glaucoma patients require more than one agent to achieve target pressure. Omidenepag can be used as part of a treatment sequence after insufficient control with another agent. Combination use raises potential prescription volume but increases price sensitivity because physicians can add generic agents at low cost.
Japan penetration
Japan is a favorable market for differentiated ophthalmic drugs because physician adoption can be influenced by tolerability, product quality and specialist prescribing. Eybelis established the product before U.S. approval and provides a base of clinical use and commercial experience.
U.S. distribution
Bausch + Lomb’s commercial infrastructure gives Omlonti access to established ophthalmology sales channels, payer negotiations and specialty-pharmacy capabilities. The arrangement reduces the need for Santen to build a wholly owned U.S. commercial organization, although economics are shared through the partnership.
What limits omidenepag isopropyl sales?
Generic price competition
The main risk is substitution by generic latanoprost, bimatoprost and travoprost. These products have extensive clinical familiarity and low out-of-pocket cost.
Formulary restrictions
Commercial insurers and Medicare Part D plans may require generic prostaglandin therapy before covering Omlonti. A restricted formulary position can reduce new starts and delay treatment switching.
Prescribing inertia
Glaucoma treatment is often managed through established stepwise regimens. Physicians may reserve newer products for patients with intolerance, inadequate control or contraindications to standard therapies.
Limited disease-modifying effect
Omidenepag lowers intraocular pressure but does not reverse optic-nerve damage or eliminate the need for monitoring. Treatment duration depends on chronic disease management, adherence and disease progression.
Commercial partner dependency
U.S. performance depends partly on the effectiveness of the Santen-Bausch + Lomb commercialization structure. Sales-force focus, payer contracting and promotional prioritization affect uptake.
What is the patent and exclusivity position for omidenepag isopropyl?
Omidenepag isopropyl is protected through a combination of compound, formulation, pharmaceutical composition and method-of-use rights. Patent scope and expiration differ by jurisdiction. The relevant commercial questions are whether patents cover the active compound, the ophthalmic formulation, dosing regimen, indication and manufacturing route.
The product’s exclusivity position is not equivalent to a single patent term. U.S. market protection depends on:
- FDA regulatory exclusivity, if granted;
- Orange Book-listed patents;
- patent-term adjustment;
- patent-term extension eligibility;
- formulation and method-of-use patents;
- Paragraph IV challenges;
- settlement agreements with generic manufacturers.
The FDA approval date was September 2022. Any applicable five-year new chemical entity exclusivity would be a key regulatory milestone, although the precise exclusivity designation and expiration must be confirmed in the FDA Orange Book and Drugs@FDA records. Patent expiry may extend beyond regulatory exclusivity, but later-expiring formulation or method-of-use patents may be harder to enforce if generic applicants carve out protected indications.
Generic-entry scenarios
| Scenario |
Likely commercial effect |
| No early Paragraph IV challenge |
Omlonti retains additional time to build formulary and physician share |
| Paragraph IV challenge without settlement |
Litigation costs rise; launch timing becomes uncertain |
| Settlement with delayed generic entry |
Predictable erosion date but possible loss of upside |
| Narrow label carve-out |
Generic entry may initially target unprotected indications |
| Full generic entry |
Rapid price and volume pressure, especially in payer-sensitive channels |
The product is a small-molecule ophthalmic drug, not a biologic. Biosimilar competition is therefore not relevant. Competitive entry would proceed through the abbreviated new drug application pathway, subject to patent and regulatory barriers.
Which companies compete most directly with omidenepag isopropyl?
The closest commercial competitors are manufacturers of prostaglandin analogs and newer mechanism-based glaucoma products.
- Viatris, Teva, Sandoz and other generic manufacturers compete through low-cost latanoprost, bimatoprost and travoprost.
- AbbVie’s Allergan business has historically held a major position in branded ophthalmic products, including Lumigan.
- Aerie Pharmaceuticals developed Rhopressa and Rocklatan, products based on netarsudil, before the ophthalmology business was acquired by Alcon.
- Santen competes with its own glaucoma portfolio while promoting omidenepag as a differentiated mechanism.
- Bausch + Lomb provides U.S. commercial reach but also operates across multiple ophthalmic categories.
Omlonti’s strongest niche is the patient who needs pressure reduction but has a clinical reason to avoid or discontinue an FP agonist. Its weakest position is untreated, price-sensitive patients with uncomplicated primary open-angle glaucoma.
What is the likely long-term financial trajectory?
The base-case trajectory is moderate specialty-pharmaceutical growth rather than blockbuster-scale expansion. Japan provides established demand, while the U.S. creates the largest incremental opportunity. Revenue should depend more on market access and switching than on diagnosis growth.
Base case
Omlonti and Eybelis gain use in patients with prostaglandin intolerance, inadequate pressure control and combination-therapy requirements. Sales grow steadily but remain limited by generic substitution.
Upside case
The product obtains favorable formulary positioning, demonstrates a clear tolerability advantage in real-world use and becomes a preferred alternative for patients who discontinue FP agonists. U.S. prescriptions expand through specialist adoption.
Downside case
Payers impose strict step therapy, physicians continue to favor generic prostaglandins, and new branded competitors capture the non-FP segment. Revenue then remains concentrated in Japan and selected U.S. specialists.
The financial profile is therefore more resilient than that of a short-course drug because glaucoma therapy is chronic, but less scalable than a high-growth specialty product because the incumbent class is genericized and clinically entrenched.
Key takeaways
- Omidenepag isopropyl is a selective EP2 agonist marketed as Eybelis in Japan and Omlonti in the United States.
- Japan approval and launch occurred in 2018; FDA approval followed in September 2022.
- The product’s main differentiation is its non-FP mechanism and potential tolerability advantages.
- Generic latanoprost and other prostaglandin analogs are the principal commercial threat.
- The U.S. market offers the largest revenue opportunity but requires favorable formulary access.
- Public filings do not disclose a complete standalone revenue history for omidenepag isopropyl.
- Biosimilar risk does not apply because omidenepag isopropyl is a small-molecule drug.
- Long-term value depends on formulation and method-of-use patent protection, regulatory exclusivity, Paragraph IV activity and payer acceptance.
- The most probable trajectory is steady specialty growth with substantial price pressure after generic entry.
FAQs about omidenepag isopropyl
Is omidenepag isopropyl a prostaglandin?
No. It is a selective EP2 receptor agonist. Its pharmacology differs from FP receptor agonists such as latanoprost, bimatoprost and travoprost.
What is the U.S. brand name for omidenepag isopropyl?
The U.S. brand name is Omlonti. Santen developed the product, and Bausch + Lomb has been associated with U.S. commercialization.
Is omidenepag isopropyl a biologic or small molecule?
It is a small-molecule ophthalmic drug. Generic competition would use the ANDA pathway rather than the biosimilar pathway.
Why might physicians prescribe omidenepag instead of latanoprost?
Potential reasons include prostaglandin intolerance, cosmetic adverse effects, inadequate pressure control or the need for a different mechanism of action.
What is the main investment risk for omidenepag isopropyl?
The main risk is limited net pricing and market share caused by generic prostaglandin competition, formulary step therapy and slow switching among established glaucoma regimens.
References
- Bausch + Lomb Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Pharmaceuticals and Medical Devices Agency. (2018). Eybelis ophthalmic solution: Review report and approval information.
- Santen Pharmaceutical Co., Ltd. (2024). Integrated report and annual securities report.
- U.S. Food and Drug Administration. (2022). FDA approves Omlonti for elevated intraocular pressure.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Omlonti prescribing information.
